You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1/PD-L1 inhibitors

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

Recruiting
  • Lung Cancer
  • Yiwu, Zhejiang, China
    The Fourth Affiliated Hospital of Zhejiang University
Dec 16, 2022

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
  • TACE
  • Nanjing, China
  • +1 more
Dec 28, 2022

Non Small Cell Lung Cancer Trial in Changsha (Anlotinib Plus Penpulimab)

Recruiting
  • Non Small Cell Lung Cancer
  • Anlotinib Plus Penpulimab
  • Changsha, Hunan, China
    Hunan Cancer hospital
Jul 17, 2022

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular

Recruiting
  • Hepatocellular Carcinoma
    • Nanjing, Jiangsu, China
      Zhongda Hospital, Southeast University
    Mar 4, 2022

    Advanced or Metastatic Urothelium Cancer Trial in Beijing (MRG002, Docetaxel Injection, Paclitaxel Injection)

    Not yet recruiting
    • Advanced or Metastatic Urothelium Cancer
    • Beijing, Beijing, China
      Cancer Hospital Chinese Academy of Medical Sciences
    Feb 22, 2023

    Non Small Cell Lung Cancer Trial in Davis, Orlando, Columbus (ONC-392, Docetaxel)

    Not yet recruiting
    • Non Small Cell Lung Cancer
    • Davis, California
    • +2 more
    Jan 5, 2023

    Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))

    Not yet recruiting
    • Gastric Adenocarcinoma
    • cadonilimab combined +paclitaxel (albumin-bound)
    • (no location specified)
    Nov 1, 2023

    Survival Outcome for Severe Immune-related Hepatitis

    Completed
    • Lung Cancer
    • PD-1/PD-L1 inhibitors
    • Changsha, Hunan, China
      Hunan Cancer hospital
    May 13, 2022

    Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

    Not yet recruiting
    • Non Small Cell Lung Cancer Recurrent
    • Toripalimab, Anlotinib and Chemotherapy
    • (no location specified)
    Apr 24, 2023

    irAE Prediction of Anti-PD-1/L1 in Lung Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • Lung Cancer
      • Beijing, China
        Peking Union Medical College Hospital
      Mar 31, 2022

      Skin Health and Quality of Life in Patients Receiving

      Not yet recruiting
      • Lung Cancer
      • +7 more
      • EQ-5D-5L questionnaire
      • +2 more
      • Roma, Italy
        Roberto Iacovelli
      May 17, 2023

      Pre-transplant ICI Exposure and Post-transplant Graft Rejection

      Recruiting
      • Graft Rejection
      • +3 more
      • Immune checkpoint inhibitor
      • Guangzhou, Guangdong, China
        Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
      Jun 21, 2023

      Oncology, Solid Tumor, Non Small Cell Lung Cancer Trial in United States (MRx0518, Pembrolizumab 25 MG/1 ML Intravenous Solution

      Active, not recruiting
      • Oncology
      • +5 more
      • MRx0518
      • Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]
      • Kansas City, Kansas
      • +4 more
      Jul 5, 2022

      Metastatic Melanoma, Immune Checkpoints Inhibitors, Gastrointestinal Microbiome (Bacterial and Viral) Trial in Ljubljana (Immune

      Recruiting
      • Metastatic Melanoma
      • +3 more
      • Immune checkpoint inhibitor
      • Ljubljana, Slovenia
        Institute of Oncology Ljubljana
      May 17, 2023

      Locally Advanced Solid Tumor, Metastatic Cancer Trial in United States (CTX-471)

      Recruiting
      • Locally Advanced Solid Tumor
      • Metastatic Cancer
      • Ocala, Florida
      • +9 more
      Sep 29, 2021

      Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma Trial

      Recruiting
      • Advanced Lung Non-Small Cell Carcinoma
      • +10 more
      • Antineoplastic Immune Cell
      • +4 more
      • Duarte, California
        City of Hope Comprehensive Cancer Center
      Aug 12, 2022

      Relapsed/Refractory Non-Hodgkin Lymphoma, Advanced Solid Tumors Trial in Beijing (Chidamide, Decitabine, Immune checkpoint

      Recruiting
      • Relapsed/Refractory Non-Hodgkin Lymphoma
      • Advanced Solid Tumors
      • Beijing, Beijing, China
        Biotherapeutic Department, Chinese PLA General Hospital
      Apr 8, 2022

      NSCLC Trial (biological, drug, radiation)

      Withdrawn
      • Non-small Cell Lung Cancer
      • avelumab
      • +21 more
      • (no location specified)
      Mar 17, 2021

      Urothelial Carcinoma, Triple Negative Breast Cancer, NSCLC Trial (SBT6290, pembrolizumab)

      Withdrawn
      • Urothelial Carcinoma
      • +4 more
      • (no location specified)
      Apr 4, 2022

      NSCLC, Small Cell Lung Cancer, Urothelial Carcinoma Trial in United States (N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 +

      Active, not recruiting
      • Non-Small Cell Lung Cancer
      • +12 more
      • N-803 + Pembrolizumab
      • +9 more
      • Anchorage, Alaska
      • +34 more
      Apr 4, 2022

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023

      Advanced Solid Tumors Trial in Grand Rapids, Houston, San Antonio (CPI-1205, ipilimumab)

      Completed
      • Advanced Solid Tumors
      • Grand Rapids, Michigan
      • +2 more
      May 16, 2022

      Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and

      Recruiting
      • HNSCC
      • +6 more
      • Conventional Therapy acc. to prevailing clincal approved schemes
      • Erlangen, Bavaria, Germany
        Department of Radiation Oncology, Universitätsklinikum Erlangen
      May 18, 2021